These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3286824)

  • 1. Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice.
    Lee K; O'Donnell RW; Marquis D; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):32-42. PubMed ID: 3286824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined effect of TNF and anticancer chemotherapeutic agents on murine bladder tumor (MBT-2)].
    Ikemoto S; Iimori H; Nishimoto K; Hayahara N; Kamizuru M; Wada S; Hayahara M
    Hinyokika Kiyo; 1992 Mar; 38(3):285-9. PubMed ID: 1523983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.
    Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M
    Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
    Silagi S; Schaefer AE
    J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of interleukin-12 against murine bladder cancer.
    Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
    J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
    Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
    Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate.
    Lee K; Erturk E; Mayer R; Cockett AT
    Cancer Res; 1987 Oct; 47(19):5021-4. PubMed ID: 2441860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
    Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in lymphocyte subsets following administration of interleukin 2 and cyclophosphamide in mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Asai Y; Kishimoto T
    Oncol Res; 1997; 9(2):71-5. PubMed ID: 9167188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
    Nitta K; Tanaka T; Takeuchi M
    Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2.
    Potapnev MP; Istomin YP; Ismail-zade RS; Zhavrid EA
    Eksp Onkol; 2004 Mar; 26(1):67-70. PubMed ID: 15112583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local low-dose IL-2 therapy.
    Den Otter W; Balemans L; Battermann JJ; Bernsen MR; Cadee JA; Dobrowolski Z; Everse LA; Fiszer-Maliszewska L; Gavhumende R; De Groot JW; De Groot K; Hennink WE; Hill FW; Jurgenliemp-Schulz I; Klein WR; Koten JW; Maas RA; Steerenberg P; Stewart R; Zembala M
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1280-6. PubMed ID: 10429975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model.
    Terao S; Shirakawa T; Goda K; Kamidono S; Fujisawa M; Gotoh A
    Anticancer Res; 2005; 25(4):2757-60. PubMed ID: 16080522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.